Ambrx Biopharma Inc. (NYSE:AMAM – Get Rating) – Analysts at B. Riley issued their Q2 2023 earnings estimates for shares of Ambrx Biopharma in a note issued to investors on Tuesday, June 13th. B. Riley analyst Y. Zhi expects that the company will earn ($0.28) per share for the quarter. B. Riley has a “Buy” […]
B. Riley started coverage on shares of Ambrx Biopharma (NYSE:AMAM – Get Rating) in a research report sent to investors on Tuesday, The Fly reports. The firm issued a buy rating and a $26.00 price target on the stock. A number of other analysts have also recently commented on the company. Robert W. Baird lifted […]
Eversept Partners LP acquired a new position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) in the 4th quarter, Holdings Channel reports. The fund acquired 91,252 shares of the company’s stock, valued at approximately $2,674,000. Other institutional investors also recently modified their holdings of the company. Cormorant Asset Management LP grew its stake […]
StockNews.com upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Rating) from a buy rating to a strong-buy rating in a research note issued to investors on Friday morning. Vanda Pharmaceuticals Stock Up 0.6 % Shares of Vanda Pharmaceuticals stock opened at $6.54 on Friday. The company’s fifty day simple moving average is $6.40 and its […]
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating)’s stock price shot up 8% on Tuesday . The company traded as high as $9.99 and last traded at $9.97. 526,724 shares were traded during mid-day trading, a decline of 39% from the average session volume of 867,447 shares. The stock had previously closed at $9.23. Analysts Set […]